Literature DB >> 21185849

An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice.

Kai Hu1, Jun Dou, Fangliu Yu, Xiangfeng He, Xianwen Yuan, Yaqing Wang, Chunsheng Liu, Ning Gu.   

Abstract

Herpes stromal keratitis (HSK) is a chronic inflammatory process caused by the infection of herpes simplex virus type 1 (HSV-1). Development of a HSV-1 vaccine is a priority because these infections are common and cannot be well prevented. It appears that the potential of nanocarriers in DNA vaccination will be required to augment the immune response to DNA vaccines. Therefore, in the study, nanoparticles Fe(3)O(4) coated with glutamic acid, DNA vaccine pRSC-gD-IL-21 and polyethylenimine were prepared and immunized in the mice by ocular mucosal administration. The immune responses and protection efficiency against HSV-1 challenge were also tested. The results showed that the nanoparticles containing DNA vaccine pRSC-gD-IL-21 induced mice to generate higher levels of specific neutralizing antibody, sIgA in tears, and IFN-γ, IL-4 in serum, and to enhance the cytotoxicities of NK cells and splenocytes as well as splenocyte proliferative response to glycoprotein D compared with those of the control mice. More importantly, the mice immunized with the experimental vaccine showed less HSK degree than that of the control mice after HSV-1 challenge of the murine ocular mucosa. In conclusion, an ocular mucosal administration of nanoparticles containing DNA vaccine confers strong specific immune responses and effective inhibition of HSK in a HSV-1 infected murine model.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21185849     DOI: 10.1016/j.vaccine.2010.12.031

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Comparison of the host immune response to herpes simplex virus 1 (HSV-1) and HSV-2 at two different mucosal sites.

Authors:  Min Zheng; Christopher D Conrady; Julie M Ward; Katie M Bryant-Hudson; Daniel J J Carr
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 2.  Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.

Authors:  Mevyn Nizard; Mariana O Diniz; Helene Roussel; Thi Tran; Luis Cs Ferreira; Cecile Badoual; Eric Tartour
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Distinguishing Features of High- and Low-Dose Vaccine against Ocular HSV-1 Infection Correlates with Recognition of Specific HSV-1-Encoded Proteins.

Authors:  Daniel J J Carr; Grzegorz B Gmyrek; Adrian Filiberti; Amanda N Berube; William P Browne; Brett M Gudgel; Virginie H Sjoelund
Journal:  Immunohorizons       Date:  2020-10-09

4.  Mice with mutations in Fas and Fas ligand demonstrate increased herpetic stromal keratitis following corneal infection with HSV-1.

Authors:  Jessica E Morris; Stephanie Zobell; Xiao-Tang Yin; Hamideh Zakeri; Bretton C Summers; David A Leib; Patrick M Stuart
Journal:  J Immunol       Date:  2011-12-07       Impact factor: 5.422

5.  Replication-defective HSV-1 effectively targets trigeminal ganglion and inhibits viral pathopoiesis by mediating interferon gamma expression in SH-SY5Y cells.

Authors:  Kun Xu; Xian-Ning Liu; Hong-Bing Zhang; Na An; Yao Wang; Zhi-Chao Zhang; Ya-Ni Wang
Journal:  J Mol Neurosci       Date:  2013-12-18       Impact factor: 3.444

6.  A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.

Authors:  Derek J Royer; Hem R Gurung; Jeremy K Jinkins; Joshua J Geltz; Jennifer L Wu; William P Halford; Daniel J J Carr
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

7.  Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.

Authors:  Brent Stanfield; Konstantin Gus Kousoulas
Journal:  Curr Clin Microbiol Rep       Date:  2015-07-01

8.  Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice.

Authors:  Grzegorz B Gmyrek; Adrian Filiberti; Micaela Montgomery; Alisha Chitrakar; Derek J Royer; Daniel J J Carr
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

9.  Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0ΔNLS vaccine against ocular HSV-1 challenge.

Authors:  Daniel J J Carr; Amanda N Berube; Adrian Filiberti; Grzegorz B Gmyrek
Journal:  Vaccine       Date:  2021-04-01       Impact factor: 3.641

10.  Mucosal immunization with live attenuated Francisella novicida U112ΔiglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat model.

Authors:  Aimee L Signarovitz; Heather J Ray; Jieh-Juen Yu; M N Guentzel; James P Chambers; Karl E Klose; Bernard P Arulanandam
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.